Quick Takeaways:
- Boehringer Ingelheim has launched Lenzelta, a new vaccine to reduce the incidence and severity of Bovine Mastitis, with a simple two-dose regimen administered during the dry-off period
- Lenzelta targets key pathogens S. aureus and E. coli, offering early onset and up to six months of protection, helping farmers proactively manage infections during the high-risk calving phase
- With EU rollout starting April 2026, Lenzelta expands Boehringer Ingelheim’s mastitis portfolio, supporting improved herd health, milk productivity, and more sustainable dairy farm operations
Why It Matters?
Lenzelta gives Boehringer Ingelheim a next‑generation mastitis vaccine that fits neatly into dry‑off protocols: two intramuscular doses in late gestation deliver early‑onset immunity and up to six months’ protection against Staph. aureus and E. coli through the high‑risk calving window.
By adding Lenzelta to its existing mastitis and udder‑health range, Boehringer can offer dairies a more prevention‑focused toolkit that aims to cut clinical case rates, somatic cell counts, and antibiotic use, supporting milk yield, animal welfare, and EU sustainability and AMR‑reduction goals as the vaccine rolls out across multiple member states from April 2026.
Source: Globenewswire
